Bromo-DragonFLY (bromo-benzodifuranil-isopropylamine) is one of the most potent and dangerous psychedelic compounds ever created. Synthesized by Matthew A. Parker in David E. Nichols' laboratory at Purdue University in 1998, it was designed as a conformationally restricted analog of DOB to study serotonin receptor structure, not for human consumption . The compound is active at sub-milligram doses (200-800 micrograms), produces psychedelic effects lasting 24 to 72 hours, and carries documented risks of life-threatening vasoconstriction, peripheral ischemia, gangrene, and death .
The name "DragonFLY" comes from the molecule's distinctive shape when drawn in structural formula: the two fused furan rings flanking the central benzene ring resemble the wings of a dragonfly. This whimsical name belies the compound's extreme toxicity profile — at least five deaths have been attributed to Bromo-DragonFLY across Scandinavia and the United States between 2007 and 2009 .
A particularly devastating incident occurred in October 2009 when a batch of Bromo-DragonFLY was mislabeled and sold as 2C-B-FLY, a structurally related but approximately 20-fold less potent compound. Users who dosed at levels appropriate for 2C-B-FLY received massively excessive amounts of Bromo-DragonFLY, resulting in multiple deaths and hospitalizations . Survivors of severe overdoses have required amputation of extremities due to irreversible gangrene caused by the compound's extreme vasoconstrictive properties.
References
- Parker, M.A. et al. Purdue University benzodifuran synthesis, 1998. Published in J. Med. Chem.
- OMICS International. "Bromo-DragonFLY: Chemistry, Pharmacology and Toxicology of a Benzodifuran Derivative Producing LSD-Like Effects."
- Andreasen, M.F. et al. "A Fatal Poisoning Involving Bromo-Dragonfly." Forensic Sci. Int., 2009.
Safety at a Glance
High Risk- It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substanc...
- On May 7, 2011, in the United States, two young adults died and several others were hospitalized after overdosing on ...
- Toxicity: Bromo-DragonFLY can be considered extremely toxic at very high dosages with several deaths and numerous hospitalizati...
- Overdose risk: overdoses. It can also have vasoconstrictive effects , which can result in severe tissue damage o...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Duration
oral
Total: 24 hrs – 96 hrsHow It Feels
The onset of Bromo-DragonFLY is treacherously slow. Hours pass after ingestion with little to show for it. A mild unease in the stomach, a faint sense that something is different, and an almost imperceptible brightening of the visual field are the only early clues. This long, quiet runway has led countless users to misjudge the dose, mistaking the delay for inactivity. By the third or fourth hour, however, the truth begins to reveal itself. A powerful stimulation builds in the body, accompanied by an escalating psychedelic intensity that makes clear this substance operates on a scale entirely different from most.
When the full force of the experience arrives, it does so with the weight and momentum of something that cannot be easily stopped. The visual field explodes with color and pattern. Geometric structures of bewildering complexity tile every surface, pulsing and shifting with an aggressive energy. The colors are vivid to the point of feeling alien, and the patterns have a hard, crystalline quality that feels more constructed than organic. The stimulation is severe. The heart pounds. Blood pressure rises. Vasoconstriction becomes pronounced, producing numbness, tingling, and sometimes pain in the extremities. The jaw clenches with sustained force, and the body temperature becomes difficult to regulate, swinging between feverish heat and cold sweats.
The cognitive effects are intense and often chaotic. Thought patterns become labyrinthine, recursive, and difficult to control. The analytical clarity of other DOx compounds is present but amplified to a degree that can become overwhelming, as the mind locks onto ideas or fears and spirals through them relentlessly. Emotional states fluctuate wildly. Moments of ecstatic wonder alternate with periods of profound anxiety and paranoia. The sense of self may fragment and rebuild repeatedly. At higher doses, full dissolution of ordinary reality is possible, giving way to immersive halluatory spaces that feel as real and consequential as the waking world.
The defining feature of Bromo-DragonFLY is its staggering duration. The peak alone can last six to twelve hours, and the total experience may stretch from twenty-four to over seventy-two hours. The comedown is not a gentle easing but a protracted ordeal of slowly diminishing intensity interleaved with residual surges of stimulation and perceptual distortion. Sleep is impossible for the duration. Physical exhaustion accumulates to dangerous levels, compounded by dehydration, appetite suppression, and sustained cardiovascular stress. When the experience finally releases its grip, the aftermath is one of deep, grateful relief and a bone-deep exhaustion that can take days to fully recover from.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(21)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Diarrhea— Diarrhea is the occurrence of frequent, loose, or watery bowel movements as a side effect of certain...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Increased salivation— Increased salivation (hypersalivation or sialorrhea) is the excessive production of saliva beyond wh...
- Mouth numbing— Mouth numbing is a localized loss of sensation in the tongue, gums, cheeks, and surrounding oral tis...
- Muscle cramp— Muscle cramps are sudden, involuntary, and often painful contractions of muscles that occur as a sid...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Stomach cramp— Stomach cramps are sharp, intermittent pains in the abdominal region that can occur when psychoactiv...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(14)
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(24)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Mindfulness— Mindfulness in the substance context refers to a state of heightened present-moment awareness in whi...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Panic attack— A panic attack is a discrete episode of acute, overwhelming fear or terror that arises suddenly and ...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(3)
- Gustatory hallucination— Gustatory hallucinations are phantom taste experiences in which distinct flavors manifest in the mou...
- Olfactory hallucination— Olfactory hallucinations (phantosmia) involve the perception of convincing phantom smells — pleasant...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Receptor Binding and Potency
Bromo-DragonFLY displays extraordinarily high affinity for serotonin receptors, with Ki values of 0.04 nM at 5-HT2A, 0.02 nM at 5-HT2C, and 0.19 nM at 5-HT2B . In functional assays, it achieves an EC50 of 0.05 nM at the 5-HT2A receptor — roughly 400-fold more potent than LSD, making it one of the most potent serotonergic agonists ever characterized . It acts as a full agonist at all three 5-HT2 receptor subtypes.
Extreme Vasoconstriction via 5-HT2B
The mechanism behind Bromo-DragonFLY's most dangerous property — severe peripheral vasoconstriction leading to tissue ischemia and gangrene — is primarily mediated through its potent full agonism at 5-HT2B receptors . The 5-HT2B receptor plays a critical role in vascular smooth muscle contraction, and Bromo-DragonFLY's sub-nanomolar affinity at this target produces sustained, intense vasoconstriction that resists standard vasodilator therapy.
In overdose cases, vasospasm has proven so severe and prolonged that tissue necrosis progresses over weeks, ultimately requiring limb amputation even when aggressive medical intervention is attempted . The compound also exhibits partial agonism at alpha-1 adrenergic receptors, further amplifying vascular tone and cardiovascular strain through increased sympathetic outflow .
Metabolic Resistance and Duration
A key factor in Bromo-DragonFLY's extreme duration (24-72 hours) is its near-complete resistance to hepatic metabolism. In vitro studies demonstrated that the compound was not metabolized in standard liver microsome and hepatocyte assays, and in a postmortem case, no metabolites could be identified in blood or urine . The compound also potently inhibits monoamine oxidase A (MAO-A) with a Ki of 0.352 micromolar, a concentration likely reached at active doses, potentially elevating endogenous monoamine levels and compounding its effects . High plasma protein binding (95.35%) and a volume of distribution around 1 L/kg contribute to prolonged tissue retention .
References
- Nichols, D.E. et al. Benzodifuran receptor binding studies. J. Med. Chem.
- Tennessee Poison Center / Vanderbilt University Medical Center. "What is Bromo-DragonFly?" Clinical toxicology review, 2016.
- Leth-Petersen, S. et al. "Bromo-dragonfly is resistant to hepatic metabolism and potently inhibits monoamine oxidase A." Toxicology Letters, 295, 2018.
- Scientific Reports. "ADME of Bromo-DragonFLY as an example of a new psychoactive substance." 2025.
Detection Methods
Urine Detection
Bromo-DragonFLY (1-(8-bromobenzo[1,2-b;4,5-b']difuran-4-yl)-2-aminopropane) is an extremely potent and long-acting psychedelic phenethylamine. Due to its amphetamine backbone, it may trigger presumptive positive results on amphetamine immunoassays. The extremely long duration of action (up to 72 hours in some cases) suggests an extended metabolic window, with potential urine detection of 3 to 5 days by LC-MS/MS methods. Limited pharmacokinetic data exists due to the rarity of the compound.
Blood and Serum Detection
Blood detection windows for Bromo-DragonFLY are estimated to be extended compared to most psychedelics, potentially 24 to 48 hours or longer, correlating with the prolonged duration of pharmacological effects. The extremely high potency (active in the microgram range) means that blood concentrations are low in absolute terms, requiring sensitive LC-MS/MS methods for detection.
Standard Drug Panel Inclusion
Bromo-DragonFLY is NOT specifically included on standard drug panels. However, like DOx compounds, cross-reactivity with amphetamine immunoassays is possible due to the intact amphetamine backbone. Confirmatory testing would not identify amphetamine, resolving any presumptive positive as negative unless the laboratory specifically tests for Bromo-DragonFLY.
Confirmatory Methods
LC-MS/MS or GC-MS with appropriate reference standards is required for definitive identification. Very few laboratories maintain reference standards for Bromo-DragonFLY due to its rarity. Forensic identification has been reported in case reports and typically requires specialized analytical development.
Reagent Testing (Harm Reduction)
The Marquis reagent produces a variable reaction, often green to brown. The Ehrlich reagent shows NO reaction, distinguishing it from lysergamides and tryptamines. Given the extreme potency and toxicity of Bromo-DragonFLY, with multiple documented fatalities, correct identification is critically important. The combination of activity on blotter paper, extremely long duration, and negative Ehrlich reaction should raise serious concern. Quantitative analysis at a laboratory is the only reliable identification method for this compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
The history of Bromo-DragonFLY is intertwined with the broader story of psychedelic research, which has oscillated between periods of intense scientific interest and strict prohibition.
Like many psychedelic compounds, Bromo-DragonFLY was either synthesized in a laboratory setting or identified as a naturally occurring psychoactive substance through ethnobotanical research. The mid-20th century saw an explosion of interest in psychedelic compounds, with researchers exploring their potential applications in psychotherapy, creativity enhancement, and the study of consciousness.
The political and cultural backlash of the late 1960s and early 1970s led to the criminalization of most psychedelic substances, effectively halting legitimate research for decades. The resurgence of psychedelic research beginning in the 2000s — often called the "psychedelic renaissance" — has renewed scientific interest in this class of compounds, with clinical trials exploring applications in treatment-resistant depression, PTSD, end-of-life anxiety, and addiction.
Bromo-DragonFLY exists within this broader pharmacological and cultural context, with its specific history shaped by its date of discovery, legal status, availability, and unique pharmacological profile.
Harm Reduction
It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the accurate administration of the intended dose.
- Notable deaths
On May 7, 2011, in the United States, two young adults died and several others were hospitalized after overdosing on Bromo-DragonFLY, which they believed was 2C-E.
Bromo-not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of Bromo-almost immediately after ingestion. After that,614 days to be back at baseline (in the absence of further consumption). Bromo-DragonFLY presents cross-tolerance with Cross-all psychedelics, meaning that after the consumption of Bromo-DragonFLY all psychedelics will have a reduced effect.
- Overdose
The risk of Bromo-DragonFLY overdose is unknown at the time, suggesting that there may not be a safe dosage. Non-oral routes also seem to exhibit a higher chance of overdosing, perhaps owing to differences in bioavailability, potency and unpredictability of dosage and effects. Overdose effects of typically include bizarre, delusional and sometimes violent behavior, amnesia, numbness, confusion and anxiety. The user may not be able to communicate and can be severely agitated. At appropriately high doses, more severe side effects include panic attacks, seizures, dangerously prolonged elevated heart rate, blood pressure and vasoconstriction. Vasoconstriction typically develops to its peak several hours into the intoxication and will need medical assistance since Bromo-DragonFLY is known to do this for an extremely long time.
The abnormally long duration of Bromo-DragonFLY poses a significant risk by staying inside the body for weeks.
Toxicity & Safety
Bromo-DragonFLY can be considered extremely toxic at very high dosages with several deaths and numerous hospitalizations reported on overdoses. It can also have extreme vasoconstrictive effects, which can result in severe tissue damage or even limb amputation. Due to its high potency, one can easily overdose if this substance is not measured correctly ("eyeballed") or mislabeled as another substance.
The toxicity and long-term health effects of recreational Bromo-DragonFLY do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because Bromo-DragonFLY is a research chemical with very little history of human usage.
It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the accurate administration of the intended dose.
Notable deaths
On May 7, 2011, in the United States, two young adults died and several others were hospitalized after overdosing on Bromo-DragonFLY, which they believed was 2C-E.
Tolerance and addiction potential
Bromo-DragonFLY is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of Bromo-DragonFLY is built almost immediately after ingestion. After that, it takes about 6 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). Bromo-DragonFLY presents cross-tolerance with all psychedelics, meaning that after the consumption of Bromo-DragonFLY all psychedelics will have a reduced effect.
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of Bromo-DragonFLY. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.
Tramadol - Tramadol is well-documented to lower the seizure threshold and psychedelics may act to trigger seizures in susceptible individuals.
Overdose
The risk of Bromo-DragonFLY overdose is unknown at the time, suggesting that there may not be a safe dosage. Non-oral routes also seem to exhibit a higher chance of overdosing, perhaps owing to differences in bioavailability, potency and unpredictability of dosage and effects. Overdose effects of typically include bizarre, delusional and sometimes violent behavior, amnesia, numbness, confusion and anxiety. The user may not be able to communicate and can be severely agitated. At appropriately high doses, more severe side effects include panic attacks, seizures, dangerously prolonged elevated heart rate, blood pressure and vasoconstriction. Vasoconstriction typically develops to its peak several hours into the intoxication and will need medical assistance since Bromo-DragonFLY is known to do this for an extremely long time.
The abnormally long duration of Bromo-DragonFLY poses a significant risk by staying inside the body for weeks.
In the event of an overdose, benzodiazepines can be administered to mitigate the hyper-agitative effects. A potent vasodilator will need to be continuously administered to prevent a hypertensive emergency, necrosis, organ failure and death from the resulting hypoxia. As a result, emergency medical services should always be sought in the event of an overdose.
Addiction Potential
not habit-forming
Overdose Information
overdoses. It can also have vasoconstrictive effects]], which can result in severe tissue damage or even limb amputation. Due to its high potency,one can easily overdose if this substance is not measured correctly ("eyeballed") or mislabeled as another substance.
The toxicity and long-term health effects of recreational Bromo-toxic dose is unknown. This is because Bromo-DragonFLY is a research chemical with very little history of human usage.
It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the accurate administration of the intended dose.
- Notable deaths
On May 7, 2011, in the United States, two young adults died and several others were hospitalized after overdosing on Bromo-DragonFLY, which they believed was 2C-E.
Bromo-not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of Bromo-almost immediately after ingestion. After that,614 days to be back at baseline (in the absence of further consumption). Bromo-DragonFLY presents cross-tolerance with Cross-all psychedelics, meaning that after the consumption of Bromo-DragonFLY all psychedelics will have a reduced effect.
- Overdose
The risk of Bromo-DragonFLY overdose is unknown at the time, suggesting that there may not be a safe dosage. Non-oral routes also seem to exhibit a higher chance of overdosing, perhaps owing to differences in bioavailability, potency and unpredictability of dosage and effects. Overdose effects of typically include bizarre, delusional and sometimes violent behavior, amnesi
Tolerance
| Full | almost immediately after ingestion |
| Half | 6 days |
| Zero | 14 days |
Cross-tolerances
Legal Status
Australia:** Bromo-DragonFLY is nationally a Schedule 9 substance, making it illegal to possess, produce and sell.
Canada:** Bromo-DragonFLY was listed as a Schedule III Substance as of October 12, 2016, along several other research chemicals.
Denmark:** Possession, production and sale is illegal.
Finland:** Possession, production and sale is illegal.
Germany:** Bromo-DragonFLY is controlled under the NpSG, as it is a derivative of 2-Phenethylamine. Production and sale is illegal. Possession and import, although illegal, is not penalized if intended for self-consumption.
Japan: Bromo-DragonFLY is a controlled substance in Japan effective August 19th, 2015.
Norway:** Bromo-DragonFLY is considered a narcotic in Norway.
Romania:** Possession, production and sale is illegal.
Sweden:** Bromo-DragonFLY is listed as a Schedule IV substance, making it illegal to possess, produce and sell.
Switzerland: Bromo-DragonFLY is likely illegal in Switzerland. It is unclear whether Bromo-DragonFLY is in the scope of a substituted a-methylphenethylamine under Verzeichnis E point 130, since it is not an "alkyl, alkoxy, alkylenedioxy or halide derivative of phenethylamine", while additionally containing further univalent substituents, according to the scope. It is also unclear if it can be considered a true ether analog of an ether analog of DOB, which would make it controlled under Buchstabe C. It could be considered an ether analog of an ether analog of para-bromoamphetamine, which would also make it illegal under Buchstabe C, but the extent of all these definitions are unknown.
Turkey:** Bromo-DragonFLY is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom** - It is illegal to produce, supply, or import this substance under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
United States:** Bromo-DragonFLY is listed as a Schedule I substance in Oklahoma.The Oklahoman, "https://www.oklahoman.com/story/news/crime/2012/08/13/man-sentenced-in-2011-designer-drug-deaths-of-two-oklahoma-college-students/61052749007/ Man sentenced in 2011 designer drug deaths of two Oklahoma college students"
Responsible use
Research chemicals
Substituted phenethylamines
Bromo-DragonFLY (Wikipedia)
Bromo-DragonFLY (Erowid Vault)
Bromo-DragonFLY (Isomer Design)
Bromo-DragonFLY (Drugs-Forum)
Experience Reports (2)
Tips (5)
Start low with Bromo-DragonFLY and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
Have a landing plan for the Bromo-DragonFLY comedown. Prepare food, melatonin or magnesium, and a comfortable environment in advance. Avoid using depressants to manage the comedown as this creates polydrug dependency patterns.
If you snort Bromo-DragonFLY, use a clean straw (never shared), crush the powder as finely as possible, alternate nostrils, and rinse with saline spray after your session. Chronic insufflation damages nasal tissue and septum.
Supplement magnesium glycinate when using Bromo-DragonFLY to reduce jaw clenching, muscle tension, and bruxism. Also maintain electrolytes, B vitamins, and vitamin C which are depleted faster under stimulant use.
Do not combine Bromo-DragonFLY with MAOIs or other serotonergic drugs. Many stimulants have serotonergic activity, and combinations can cause serotonin syndrome or hypertensive crisis, both medical emergencies.
See Also
Same Class
References (5)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- PubChem: Bromo-DragonFLY
PubChem compound page for Bromo-DragonFLY (CID: 10544447)
pubchem - Bromo-DragonFLY - TripSit Factsheet
TripSit factsheet for Bromo-DragonFLY
tripsit - Bromo-DragonFLY - Wikipedia
Wikipedia article on Bromo-DragonFLY
wikipedia